Hereditary Hemorrhagic Telangiectasia
It is possible that the main title of the report Hereditary Hemorrhagic Telangiectasia is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.
- Osler-Weber Rendu Syndrome
- Rendu-Osler-Weber Syndrome
Hereditary hemorrhagic telangiectasia (HHT or Osler-Weber-Rendu syndrome) is an inherited disorder characterized by malformations of various blood vessels (vascular dysplasia), usually resulting in bleeding (hemorrhaging). Chronic nosebleeds are often the first sign and malformation of various blood vessels may result in abnormalities affecting the lungs, brain, spinal cord, and liver. A variety of treatments exist for the various features of HHT to improve quality of life and prevent life-threatening complications Individuals with HHT have a near-normal life expectancy. HHT is inherited as an autosomal dominant trait.
HHT was first described by Henry Gawen Sutton in 1864. With similar symptoms to hemophilia the two diseases were differentiated by Henri Jules Louis Marie Rendu in 1896. William Osler connected the disease's presence in families to establish it as an inherited disorder. In 1907 Frederick Parkes Weber continued the characterization of the disease, writing a report on a series of cases. In 1909, the name "hereditary hemorrhagic telangiectasia" was coined, but alternate names based on the scientists who first characterized it have also been commonly used. Since its first identification, HHT has been an underdiagnosed disease, affecting more than a million people worldwide.
March of Dimes Birth Defects Foundation
1275 Mamaroneck Avenue
White Plains, NY 10605
HHT Foundation International, Inc.
P.O. Box 329
Monkton, MD 21111
Genetic and Rare Diseases (GARD) Information Center
PO Box 8126
Gaithersburg, MD 20898-8126
PO Box 241956
Los Angeles, CA 90024